MaxCyte STX Antibody Production Shown to be Reproducible and Scalable
Gaithersburg, MD, March 31, 2015 – MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems announces the publication of its technical note, “CHO-S Antibody Titers >1 Gram/Liter Using Flow Electroporation-Mediated Transient Gene Expression followed by Rapid Migration to High-Yield Stable Cell Lines,” in the April 2015 issue of the Journal of Biomolecular Screening.
The article presents data demonstrating the reproducibility, scalability, and antibody production capabilities of CHO-based transient transfection using the MaxCyte STX® Scalable Transfection System. “Success for pharmaceutical companies depends on their ability to get to market quickly,” noted Dr. James Brady, Vice President of Technical Application and Customer Service, MaxCyte. “In this article, we show that within just 2 weeks of a single CHO-S cell transfection and with optimization of post transfection parameters such as cell density, media composition, and feed strategy, secreted antibody titers of >1 g/L can be achieved, which is equal to the production of multiple grams of antibody.”
Key results presented in the article include:
The entire article can be accessed at //jbx.sagepub.com/content/20/4/545.full.
MaxCyte specializes in cell modification technologies for innovative therapeutic products. MaxCyte’s portfolio of products—the MaxCyte STX® Scalable Transfection System, MaxCyte VLX® Large Scale Transfection System, and MaxCyte GT® Scalable Transfection System—make possible the discovery and development of small molecule drugs, biotherapeutics, and pioneering cellular therapeutics. MaxCyte’s products enable the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and other cell lines for protein and antibody production, rapid response vaccine development, cell-based assays, and state-of-the-art cell-based therapeutics.
For more information visit /
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter